Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6

Pharmacogenomics. 2016 Aug;17(12):1291-3. doi: 10.2217/pgs-2016-0105. Epub 2016 Jul 29.

Almudena Sánchez-Martín^{1

2}, Santiago Sánchez-Iglesias^{2

3}, Belén García-Berrocal^{2

4}, Carolina Lorenzo^{2

3}, Andrea Gaedigk^{5

6}, María Isidoro-García^{2

4

7}

¹ Department of Pharmacy, University Hospital of Salamanca, Salamanca, Spain.
² IBSAL, Salamanca Institute for Biomedical Research, Salamanca, Spain.
³ Department of Psychiatry, University Hospital of Salamanca, Spain.
⁴ Department of Clinical Biochemistry, University Hospital of Salamanca, Spain.
⁵ Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital, Kansas City, MO, USA.
⁶ Department of Pediatrics, School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.
⁷ Department of Medicine, University of Salamanca, Spain.

No abstract available

Keywords: CYP2D6; adverse event; bipolar disorder; pharmacogenetics.

Publication types